Implantable medical devices comprising bio-degradable alloys with enhanced degradation rates

US10765775B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10765775-B2
Application numberUS-201916255093-A
CountryUS
Kind codeB2
Filing dateJan 23, 2019
Priority dateMar 14, 2013
Publication dateSep 8, 2020
Grant dateSep 8, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention provides medical devices comprising high-strength alloys which degrade over time in the body of a human or animal, at controlled degradation rates, without generating emboli and which have enhanced degradation due to the presence of a halogen component. In one embodiment the alloy is formed into a bone fixation device such as an anchor, screw, plate, support or rod. In another embodiment the alloy is formed into a tissue fastening device such as staple. In yet another embodiment, the alloy is formed into a dental implant or a stent.

First claim

Opening claim text (preview).

What is claimed: 1. A method of producing a biodegradable alloy that is austenitic in structure and includes iron, at least one additional metallic element, and an iron reactive component, wherein the iron reactive component is dispersed within the biodegradable alloy at a concentration between about 0.1 ppm to about 500 ppm, and wherein the degradation rate of the biodegradable alloy, when implanted in a biological subject, is greater than the degradation rate of an alloy having the same composition as the biodegradable alloy except the absence of the iron reactive component, the method comprising: melting iron, the at least one additional metallic element, and a salt containing the iron reactive component to produce a mixture; and contacting the mixture with a gas containing the iron reactive component to produce the biodegradable alloy. 2. The method of claim 1 , wherein the salt containing the iron reactive component is selected from the group consisting of sodium fluoride, sodium chloride, copper chloride, copper fluoride, magnesium chloride, silver chloride, calcium chloride, calcium fluoride, iron chloride, and a combination thereof. 3. The method of claim 1 , wherein the gas containing the iron reactive component has a partial pressure of at least about 0.1 torr, at least about 0.2 torr, at least about 0.5 torr, at least about 0.8 torr, at least about 1 torr, at least about 2 torr, at least about 5 torr, at least about 10 torr, at least about 50 torr, or at least about 100 torr. 4. The method of claim 1 , the iron reactive component is a halogen component. 5. The method of claim 4 , wherein the halogen component is selected from the group consisting of chloride, fluoride, bromide, and iodide. 6. The method of claim 5 , wherein the halogen component is chloride or fluoride. 7. The method of claim 5 , wherein the gas containing the iron reactive component is selected from the group consisting of chlorine, fluorine, bromine, and iodine. 8. The method of claim 1 , further comprising mixing the iron reactive component with argon gas to produce the gas containing the iron reactive component. 9. The method of claim 8 , wherein the argon gas has a partial pressure of at least about 10 torr, at least about 20 torr, at least about 50 torr, at least about 80 torr, at least about 100 torr, at least about 150 torr, at least about 200 torr, at least about 250 torr, at least about 300 torr, or at least about 500 torr. 10. The method of claim 1 , wherein the biodegradable alloy includes an austenite-promoting component and a corrosion-resisting component. 11. The method of claim 1 , wherein the biodegradable alloy contains between about 20% to 40% manganese by weight. 12. The method of claim 1 , wherein the biodegradable alloy contains less than about 0.3% niobium by weight. 13. The method of claim 1 , wherein the biodegradable alloy contains less than about 1% carbon by weight. 14. The method of claim 1 , wherein the biodegradable alloy includes manganese and niobium. 15. The method of claim 1 , wherein the biodegradable alloy includes at least about 0.01% to about 0.1% a non-metallic element by weight. 16. The method of claim 15 , wherein the biodegradable alloy includes at least about 0.01% to about 0.1% carbon by weight. 17. The method of claim 1 , wherein the biodegradable alloy is in a form of an implantable medical device. 18. The method of claim 17 , wherein the implantable medical device is a bone screw, a bone anchor, a tissue staple, a craniomaxillofacial reconstruction plate, a fastener, a reconstructive dental implant, or a stent. 19. The method of claim 17 , further comprising coating the implantable medical device with a therapeutic agent. 20. The method of claim 17 , further comprising coating the implantable medical device with a biodegradable hydrogel. 21. The method of claim 17 , wherein the implantable medical device has a geometry that maximizes the surface to mass ratio. 22. The method of claim 17 , wherein the implantable medical device includes a hollow opening or passageway formed therein. 23. The method of claim 1 , wherein the concentration of the iron reactive component in the biodegradable alloy is between about 1 ppm to about 500 ppm, between about 10 ppm to about 300 ppm, or between about 50 ppm to about 150 ppm. 24. The method of claim 1 , wherein the concentration of the iron reactive component in the biodegradable alloy is about 200 ppm. 25. The method of claim 1 , wherein the iron, the at least one additional metallic element, and the salt containing the iron reactive component are melted in the presence of the gas containing the iron reactive component. 26. A biodegradable alloy produced by the method of claim 1 .

Assignees

Inventors

Classifications

  • A61C8/0012Primary

    characterised by the material or composition, e.g. ceramics, surface layer, metal alloy (use of specific materials A61K6/00) · CPC title

  • Materials at least partially resorbable by the body · CPC title

  • Metals or alloys · CPC title

  • Workpiece with longitudinal passageway or stopweld material [e.g., for tubular stock, etc.] · CPC title

  • A61L27/042Primary

    Iron or iron alloys · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10765775B2 cover?
The invention provides medical devices comprising high-strength alloys which degrade over time in the body of a human or animal, at controlled degradation rates, without generating emboli and which have enhanced degradation due to the presence of a halogen component. In one embodiment the alloy is formed into a bone fixation device such as an anchor, screw, plate, support or rod. In another emb…
Who is the assignee on this patent?
Bio Dg Inc, Us Dept Energy
What technology area does this patent fall under?
Primary CPC classification A61C8/0012. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Sep 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).